Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Fineline Cube Dec 13, 2025
Company Deals

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Fineline Cube Dec 13, 2025
Company Drug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA Releases Guide on Volume-Based Procurement Drug Equivalents

Fineline Cube Sep 22, 2022

The National Healthcare Security Administration (NHSA) has reportedly released a reference guide for industry players,...

Company Drug

Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE

Fineline Cube Sep 22, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Deals Policy / Regulatory

F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review

Fineline Cube Sep 22, 2022

UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...

Company Deals Digital

Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine

Fineline Cube Sep 22, 2022

Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round...

Company

Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center

Fineline Cube Sep 22, 2022

German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of...

Company Deals

METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program

Fineline Cube Sep 22, 2022

Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...

Policy / Regulatory

Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme

Fineline Cube Sep 22, 2022

Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...

Company Deals

Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare

Fineline Cube Sep 21, 2022

Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...

Company Drug

Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA

Fineline Cube Sep 21, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...

Company Deals

Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2

Fineline Cube Sep 21, 2022

Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...

Company Drug

Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Deals

Koutech Robotics Secures Series A Funding for Surgical Innovation

Fineline Cube Sep 21, 2022

China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...

Company Drug

CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit

Fineline Cube Sep 21, 2022

China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...

Company Deals

Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...

Company

Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development

Fineline Cube Sep 21, 2022

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million...

Policy / Regulatory

Beijing Designates 923 Medical Entities for National Reimbursement Drug List

Fineline Cube Sep 21, 2022

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...

Company

Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift

Fineline Cube Sep 20, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...

Company Drug

Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China

Fineline Cube Sep 20, 2022

China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...

Company Drug

Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study

Fineline Cube Sep 20, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...

Company Deals

WuXi Biologics Partners with Elpiscience for Macromolecule Development

Fineline Cube Sep 20, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...

Posts pagination

1 … 553 554 555 … 596

Recent updates

  • InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
  • Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
  • GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
  • B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
  • OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.